TransCode Therapeutics
RNAZ
8 hedge funds and large institutions have $155K invested in TransCode Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
1.91% less ownership
Funds ownership: 3.65% → 1.73% (-1.9%)
11% less funds holding
Funds holding: 9 → 8 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
35% less capital invested
Capital invested by funds: $237K → $155K (-$82K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$122K |
| 2 |
Citigroup
New York
|
+$16.5K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$219K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11.2K |
| 3 |
SC
SouthState Corp
Winter Haven,
Florida
|
-$3.76K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.71K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$23 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $126K | +$122K | +11,702 | New |
|
|
2
Citigroup
New York
| $17K | +$16.5K | +1,586 | New |
|
|
FDCDDQ
3
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $10.5K | +$10.2K | +975 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1.53K | -$2.71K | -260 | -65% |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $108 | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $86 | – | – | – |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $29 | – | – | – |
|
|
8
Goldman Sachs
New York
| – | -$219K | -28,042 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$11.2K | -1,432 | Closed |
|
|
SC
10
SouthState Corp
Winter Haven,
Florida
| – | -$3.76K | -482 | Closed |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| – | -$23 | -3 | Closed |
|
RNAZ Hedge Fund Activity: Q3 2025 in Review
8 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q3 2025, worth a combined $155K — down 35% from $237K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RNAZ and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was DRW Securities, opening a new position worth an estimated $122K. The largest seller was Goldman Sachs, exiting entirely with an estimated $219K sold.
- 8 institutional investors held TransCode Therapeutics (RNAZ) as of Q3 2025, down from 9 in Q2 2025.
- Funds reported $155K of TransCode Therapeutics stock for Q3 2025, down 35% quarter-over-quarter.
- 3 funds opened new TransCode Therapeutics positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest TransCode Therapeutics buyer in Q3 2025 was DRW Securities, an estimated $122K added.
- The largest TransCode Therapeutics seller in Q3 2025 was Goldman Sachs, an estimated $219K sold.
Based on aggregated 13F filings for Q3 2025.